- World’s first epigenetic patent filed for ‘Natural Substance PBM’
- Proven overwhelming efficacy in animal trials: A reverse-aging solution that awakens dormant hair follicles

ROKIT Healthcare (KOSDAQ 376900), a specialist in AI-driven hyper-personalized organ regeneration platforms, announced today that it has filed a world-first patent for “Natural Substance PBM Epigenetics” and will officially commence human clinical trials this March. The groundbreaking technology has already demonstrated full hair regrowth within just four weeks of administration in preclinical tests.

This achievement utilizes the Photobiomodulation (PBM) mechanism, which regulates biological activity in response to light. It represents a key milestone in ROKIT Healthcare’s "Reverse-Aging" project, a core focus of the company for the past four years. Moving beyond simple symptom relief, this technology employs an epigenetic approach to restore the microenvironment of aged hair follicles to a more youthful state.

The most significant differentiator of ROKIT’s technology is its fundamental approach. While conventional hair loss treatments typically focus on “blocking” male hormones from attacking follicles, ROKIT’s reverse-aging solution focuses on “waking up” dormant hair follicle cells.

Preclinical trials conducted on animal models have yielded overwhelming results. The experimental group treated with the natural candidate substance showed full hair regrowth (Full Regrowth) by the fourth week. This result highlights a clear epigenetic regeneration pattern, where positive changes initiated at the skin surface reach deep into the follicles to restore the body’s innate regenerative capacity—a significantly faster recovery compared to existing treatments.

The solution also stands out for its safety profile. Unlike many current hair loss drugs that rely on hormone suppression and carry risks of side effects such as sexual dysfunction, ROKIT’s solution utilizes highly safe natural substances.

These natural compounds act similarly to cellular photosynthesis, restoring the normal signaling pathways from the epidermis to the hair follicle. This induces explosive hair follicle cell division through an epigenetic mechanism, facilitating rapid and healthy hair growth.

According to global market research firm Grand View Research, the global hair loss treatment market is projected to grow rapidly to approximately $16 billion (approx. 23.5 trillion KRW) by 2030.

“This achievement proves the power of true ‘reverse-aging technology’ by combining natural substances with advanced PBM to trigger epigenetic regeneration in skin and follicle tissues,” said an official from ROKIT Healthcare. “In particular, the preclinical result of full regrowth in four weeks is powerful evidence of this technology’s commercial potential and its capacity to disrupt the market.”

Building on the successful patent filing and preclinical results, ROKIT Healthcare plans to accelerate human clinical validation starting in March. The company aims to introduce this innovative solution to the global market by integrating it with its proprietary AI-driven organ regeneration and reverse-aging platforms.